Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-centre Study to Assess ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)

NCT00090363 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00090363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00090363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-centre Study to Assess ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2004
Completion date
August 31, 2011
Enrollment
447 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer